TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00657878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stealth liposomal doxorubicin
Description: stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stealth liposomal doxorubicin
Description: stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin AUC 5 IV day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: carboplatin AUC 5 IV day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 175 mg/m2 IV day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 175 mg/m2 IV day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: dosing and schedule according to Institutional guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: dosing and schedule according to Institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 on days 1,8,15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 on days 1,8,15 every 28 days
Study: NCT00686803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL3994
Description: Study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL3994
Description: Study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL3994
Description: Study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL3994
Description: Study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL3994
Description: Study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03872700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Description: Fentanyl Citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile Water Up to 5Cc
Study: NCT00389311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normosol-R
Study: NCT02896855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Study: NCT01792089

Intervention type: OTHER
Intervention: fat+protein meal
Description: cream+ whey protein
Study: NCT04525690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Clinicians will receive a default order upon entering the the admission order set. They will have the opportunity to opt-out and not order screening. Clinicians will receive the nudge each time they enter the admission order set for a new, eligible patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Clinicians will receive a default order upon entering the the admission order set. They will have the opportunity to opt-out and not order screening. Clinicians will receive the nudge each time they enter the admission order set for a new, eligible patient.
Study: NCT02602340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation therapy
Description: Behavioral Activation therapy
Study: NCT01439841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic
Description: The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fermented and subsequently heat-treated, sterile skimmed milk
Study: NCT02844179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTBZ
Study: NCT04846218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Study: NCT03849794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 40 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 15 minutes in duration.
Study: NCT05385029

Intervention type: DRUG
Intervention: Thyroxine
Description: treatment for hypothyroidism or hyperthyroidism

Intervention type: DRUG
Intervention: Thyroxine
Description: treatment for hypothyroidism or hyperthyroidism
Study: NCT04116294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-assisted prescription
Description: The intervention is based on a computer-assisted prescription: when a PAR will be ordered, an alert will arise and explain the recognized indications for this examination and ask a confirmation for the prescription. This is a non-blocking system: physicians will be able to prescribe PAR even if the PAR is not appropriate.
Study: NCT01792089

Intervention type: OTHER
Intervention: fat+protein meal
Description: cream+ whey protein

Intervention type: OTHER
Intervention: fat+protein meal
Description: cream+ whey protein

Intervention type: OTHER
Intervention: Fat + protein + 13C fructose meal
Description: cream+ whey protein +13C fructose

Intervention type: OTHER
Intervention: Fat + protein + 13C fructose meal
Description: cream+ whey protein +13C fructose

Intervention type: OTHER
Intervention: Fat + protein + 13C fructose meal
Description: cream+ whey protein +13C fructose

Intervention type: OTHER
Intervention: Fat+protein+13C fructose+glucose meal
Description: Cream + whey protein + glucose:13C fructose mixture

Intervention type: OTHER
Intervention: 13C Fat + whey protein
Description: cream labelled with 13C palmitate + whey protein

Intervention type: OTHER
Intervention: 13C Fat + whey protein + glucose+ glucose meal
Description: cream labelled with 13C palmitate + whey protein + glucose:fructose mixture

Intervention type: OTHER
Intervention: 13C Fat + whey protein + glucose+ glucose meal
Description: cream labelled with 13C palmitate + whey protein + glucose:fructose mixture

Intervention type: OTHER
Intervention: 13C Fat + whey protein + glucose+ glucose meal
Description: cream labelled with 13C palmitate + whey protein + glucose:fructose mixture
Study: NCT02038985

Intervention type: OTHER
Group type: OTHER
Intervention: Participants will receive ICG Dye
Description: Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
Study: NCT00035165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epothilone b
Description: intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
Study: NCT03582293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 500Mg Tablet
Description: orally twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral placebo capsule two times a day for a total of 28 days
Study: NCT01710826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genz-682452
Description: Capsules for oral administration.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching the Genz-682452 capsules.
Study: NCT05455970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS)
Description: A therapeutic application of pulsed rhythmic or musical stimulation in order to improve gait or movement
Study: NCT03551938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship skills session for YMSM partnered-individuals and couples
Description: Relationship skills session as an addition to the current CTR and CHTC intervention for 15-24 year old YMSM and their partners.
Study: NCT02575846

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Intake - Human Milk
Description: Comparing formula and human milk
Study: NCT01811797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Shockwave by Renova
Study: NCT02575846

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Enteral Intake - Formula
Description: Comparing formula and human milk
Study: NCT02103439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algeron
Description: 1.5 µg/kg of body weight subcutaneously, once a week
Study: NCT01811797

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment that looks, sounds and feels like the real LISW treatment.
Study: NCT04523415

Intervention type: OTHER
Intervention: without intervention, just retrospectively review the data about patients
Description: without intervention
Study: NCT01488266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5\~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: switching to different class of antidepressant
Description: Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
Study: NCT02103439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron
Description: 1.5 µg/kg of body weight subcutaneously, once a week
Study: NCT01925716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corn oil
Description: corn oil 56 g/day for 21 days
Study: NCT02864680

Intervention type: OTHER
Group type: OTHER
Intervention: Electroretinography

Intervention type: OTHER
Group type: OTHER
Intervention: Electroretinography

Intervention type: OTHER
Group type: OTHER
Intervention: Electroretinography

Intervention type: OTHER
Group type: OTHER
Intervention: Electroretinography
Study: NCT00389311

Intervention type: DRUG
Group type: OTHER
Intervention: Normosol-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nonoxynol-9

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal instrumentation
Study: NCT02708628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extract of allium cepae, allantoin and heparin
Description: prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
Study: NCT01925716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corn oil
Description: corn oil 56 g/day for 21 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: olive oil 56 g /day for 21 days
Study: NCT02864680

Intervention type: OTHER
Group type: OTHER
Intervention: Spatial Working Memory (SWM) test

Intervention type: OTHER
Group type: OTHER
Intervention: Spatial Working Memory (SWM) test

Intervention type: OTHER
Group type: OTHER
Intervention: Spatial Working Memory (SWM) test

Intervention type: OTHER
Group type: OTHER
Intervention: Rapid Visual Information Processing (RVP) test

Intervention type: OTHER
Group type: OTHER
Intervention: Rapid Visual Information Processing (RVP) test

Intervention type: OTHER
Group type: OTHER
Intervention: Rapid Visual Information Processing (RVP) test

Intervention type: OTHER
Group type: OTHER
Intervention: Rapid Visual Information Processing (RVP) test

Intervention type: OTHER
Group type: OTHER
Intervention: Test for attentional performance (TAP) / Divided Attention

Intervention type: OTHER
Group type: OTHER
Intervention: Test for attentional performance (TAP) / Divided Attention

Intervention type: OTHER
Group type: OTHER
Intervention: Test for attentional performance (TAP) / Divided Attention

Intervention type: OTHER
Group type: OTHER
Intervention: Test for attentional performance (TAP) / Divided Attention

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of saliva sample
Description: In case of specific consent of participant to ancillary study, for ancillary study

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of saliva sample
Description: In case of specific consent of participant to ancillary study, for ancillary study

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of saliva sample
Description: In case of specific consent of participant to ancillary study, for ancillary study

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of saliva sample
Description: In case of specific consent of participant to ancillary study, for ancillary study
Study: NCT00619086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethason Helvepharm ®
Description: 8 mg Dexamethason i.v. 45 minutes prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml sodium chloride i.v. 45 minutes prior to surgery
Study: NCT03564756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000mg Vitamin C per day
Study: NCT01363609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment 12 weeks
Description: liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine treatment
Description: Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration \< 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day

Intervention type: DRUG
Group type: OTHER
Intervention: GLP-1 receptor antagonist
Description: Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
Study: NCT01960933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR
Study: NCT01535846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscious food tasting intervention
Description: Six weekly 2-hour workshops
Study: NCT04559165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sericin and chitosan cream
Description: sericin and chitosan cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sericin and chitosan cream
Description: sericin and chitosan cream
Study: NCT00931385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744
Description: BI1744 Respimat Med Dose Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bi1744
Description: 1744 low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Respimat and Foradil Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil
Description: Foradil 12 mcg twice daily and Placebo Respimat
Study: NCT02594345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: in vitro study
Description: Exosomes will be mixed with healthy volunteers' blood in vitro
Study: NCT01418729

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pravastatin
Description: Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
Study: NCT02232139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The participants receive the pharmacological premedication before the surgery anyway
Study: NCT00711867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VH2
Description: Dynatherm vitalHeat2 (VH2) temperature management system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger
Description: Arizant Bair Hugger temperature management system.
Study: NCT03751020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW) Intervention
Description: The EW intervention will utilize the procedures piloted earlier with gay and bisexual male college students in urban and rural regions of the US. In this condition, participants will be instructed to write for 20 minutes across three consecutive days in a free-form manner about the most stressful or traumatic LGB-related event that they have encountered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Affirmation (SA) Intervention
Description: The SA intervention will ask participants to read a brief description, over the course of 3 consecutive days, of a (hypothetical) LGB youth who is facing minority stress. Each day's description will contain a different LGB youth facing a different stigma-related stressor derived from Phase 1 and 2 interviews. Participants will then be asked to write a letter for 20 minutes to advise the LGB youth how best to cope with minority stress drawing on their personal experiences.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days. This control matches the time and activity of the EW and SA arms and has been implemented across dozens of EW and SA studies.
Study: NCT01824069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of a suspension of adult mesenchymal stem cells derived
Description: Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
Study: NCT04175873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: Patients will listen to music with MP3 headphones for 1 hour preoperatively and throughout the operation.
Study: NCT04322968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.
Description: Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.
Description: Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.
Description: Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.
Description: Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
Study: NCT01559974

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to 45'000 units of Cholecalciferol per month for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 45'000 units of cholecalciferol per month for 3 months
Study: NCT00038129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary nail implant
Description: Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary nail implant
Description: Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.